Related Experiment Video
Updated: Jun 26, 2026
Myocardial Infarction and Functional Outcome Assessment in Pigs
Published on: April 25, 2014
Role of risk stratification after myocardial infarction
Vikas Kuriachan1, Derek V Exner
1Derek V. Exner, MD, MPH Libin Cardiovascular Institute of Alberta, University of Calgary, 3330 Hospital Drive NW, Room G208, Calgary, AB, Canada T2N 4N1. exner@ucalgary.ca.
Insights
Sudden cardiac death after myocardial infarction (MI) is a major concern. New tests assessing cardiac structure and autonomic function may improve risk stratification for implantable defibrillator therapy beyond current methods.
Area of Science:
- Cardiology
- Public Health
- Medical Technology
Background:
- Sudden cardiac death (SCD) is a significant public health issue, particularly affecting patients post-myocardial infarction (MI).
- Current risk stratification using severe left ventricular (LV) systolic dysfunction is insufficient, as most SCDs occur in patients with mild LV dysfunction.
- Accurate identification of high-risk patients is crucial for guiding implantable defibrillator (ICD) therapy.
Purpose of the Study:
- To investigate novel risk stratification methods for identifying patients at high risk of sudden cardiac death after MI.
- To evaluate the potential of combining various tests (cardiac structure, repolarization, autonomic modulation) for improved risk prediction.
- To determine if these combined tests can guide implantable defibrillator therapy decisions.
Main Methods:
- Review of existing and emerging diagnostic tests for cardiac arrest risk assessment post-MI.
- Focus on tests evaluating cardiac structure, repolarization abnormalities, and autonomic nervous system modulation.
- Consideration of the combined utility of multiple risk assessment tools.
Main Results:
- Most sudden cardiac arrests after MI occur in patients with mild LV dysfunction, highlighting limitations of current criteria.
- Combining multiple tests assessing cardiac structure, repolarization, and autonomic function shows promise in identifying high-risk individuals.
- No single test has proven sufficient for predicting sudden death risk or guiding ICD therapy.
Conclusions:
- Severe LV dysfunction is currently the sole proven criterion for guiding ICD therapy post-MI.
- Emerging tests assessing cardiac structure and autonomic function, especially in combination, may offer improved risk stratification.
- Further randomized controlled trials are necessary to validate the use of these novel tests in guiding ICD therapy decisions.
Abstract:
Despite advances in medical and surgical therapy for patients with heart disease, sudden cardiac death remains an important public health problem that prematurely ends the lives of more than 300,000 persons each year in North America. Many of these deaths occur in patients with a history of myocardial infarction (MI). Although severe left ventricular (LV) systolic dysfunction is used to identify patients at risk of sudden death after MI, most cardiac arrests occur in those with only mild LV dysfunction. Further, severe LV dysfunction is not a specific indicator for cardiac arrest. Risk stratification, to identify patients most likely to benefit from implantable defibrillator therapy after MI, is an essential area of investigation. Because the development of cardiac arrest is complex and likely requires the confluence of several factors, using a single test to predict the risk of sudden death or to guide implantable defibrillator therapy is unlikely to be successful. Tests that assess cardiac structure, including repolarization, and those that evaluate autonomic modulation and other factors have been developed with the goal of identifying patients at highest risk of cardiac arrest after MI. These tests, particularly in combination, appear to identify patients who may benefit from implantable defibrillator therapy after MI. Ongoing and planned randomized controlled trials will assess whether these tests can be used to guide implantable defibrillator therapy. Until the data from these studies are available, severe LV dysfunction remains the only proven approach to guide implantable defibrillator therapy after MI.
Related Concept Videos
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:30Acute Coronary Syndrome I: Introduction
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:25Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
01:30Heart Failure IV: Classification and Diagnostic Evaluation
01:26Atherosclerosis III: Management